Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept

Table 2

Trials of anti EGFR monoclonal antibodies.

	Phase	Number of patients	Anatomic site	Histology	Treatment regimen	Outcomes	Comments
Gold et al. [21]	II	55	Esophagus	55/55 adenocarcinoma	Cetuximab 400 mg/m^2 IV×1, then 250 mg/m^2 IV weekly	mOS 4 months mPFS 1.8 months	2nd line treatment
Ku et al. [22]	II	8	Esophagus/GEJ	7/8 adenocarcinoma (87%) 1/8 squamous cell (13%)	CPT 11 65 mg/m^2  + Cisplatin 30 mg/m^2 weekly 2/3 weeks Cetuximab 400 mg/m^2  × 1, then 250 mg/m^2 IV weekly	mTTP 4.4 months 1 PR, 2 SD	All patients received prior CPT 11/cisplatin Accrual ongoing
Pinto et al. [23]	II	38	34/38 Gastric 4/38 GEJ	38/38 adenocarcinoma	CPT 11 180 mg/m^2 IV D1 5-FU 400 mg/m^2 IV bolus D1, 5-FU 600 mg/m^2 CIVI D1-2, Leucovorin 100 mg/m^2 IV D1 every 2 weeks  × 24 weeks (FOLFIRI) Cetuximab 400 mg/m^2  × 1, then 250 mg/m^2 IV weekly	mTTP 8 months median expected survival 16 months 4/34 CR (12%), 11/34 PR (32%), 16/34 SD (47%)	Untreated advanced/ metastatic disease
Han et al. [24]	II	38	38/38 gastric	38/38 adenocarcinoma	Oxaliplatin 100 mg/m^2 IV D1 Leucovorin 100 mg/m^2 IV D1, 5-FU 1200 mg/m^2/d CIVI  × 46 hours (mFOLFOX6) Cetuximab 400 mg/m^2  × 1, then 250 mg/m^2IV weekly	mTTP 5.5 months mOS 9.9 months 19/38 PR (50%), 16/38 SD (42%)	EGF and TGF-alpha levels inversely correlated with response

mOS: median overall survival; mPFS: median progression free survival; PR: partial response; SD: stable disease; GEJ: gastroesophageal junction; TTF: time to failure; TTP: time to progression; CPT 11: irinotecan; EGF: epidermal growth factor; TGF-alpha: transforming growth factor-alpha.